Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals, Inc. (ANTH) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
anth · stock forecast · 12 analysts (3M) · FMP · updated Dec 4, 2023
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.00
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ANTH · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2018-02-21 | Roth Capital | Maintains | Buy→Buy |
| 2016-12-29 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2016-12-29 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2015-09-17 | Citigroup | Maintains | Buy→Buy |
| 2015-05-12 | Citigroup | Upgrade ↑ | Sell→Neutral |
| 2015-03-17 | Jefferies | Maintains | Buy→Buy |
| 2013-03-28 | McNicoll Lewis Vlak | Maintains | Buy→Buy |
| 2013-03-05 | Jefferies | Maintains | Buy→Buy |
| 2012-07-09 | Canaccord Genuity | Maintains | Buy→Buy |
| 2012-06-29 | Ascendiant Capital | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on Anthera Pharmaceuticals, Inc. (ANTH) stock. Of the recent 20 rating actions, 1 were upgrades and 6 were downgrades. 12 analysts currently cover ANTH.
Analyst Recommendation Trends
ANTH analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$5M
EPS This Year
$-2.19
EPS Next Year
$-1.54
↓ 29.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast ANTH EPS of $-2.19 for the current fiscal year, based on estimates from 1 analysts. The ANTH revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ANTH stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ANTH price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The ANTH short-term stock prediction for tomorrow is $0.00 (+0.00%).
Anthera Pharmaceuticals, Inc. trades on OTC under the ticker ANTH. The ANTH stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
ANTH forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month ANTH price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.